Targeting treatment-resistant ovarian cancer
Official title: Targeting chemotherapy resistant high grade serous ovarian cancer
Funded at University of Texas Hlth Science Center · NIH-10908705 · Data updated 2026-11-12
This study is looking at how a protein called LIF makes high-grade serous ovarian cancer cells resistant to chemotherapy, and it aims to find ways to block this protein so that treatments can work better for patients facing this tough cancer.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Texas Hlth Science Center NIH-funded |
| Lab location | 1 site (San Antonio, United States) |
| Project start | August 16, 2023 |
| Project end | July 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $36,300 |
| NIH project number | 5F99CA284284-02 |
| Project ID | NIH-10908705 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with high-grade serous ovarian cancer who have experienced chemotherapy resistance.
✕Less likely to help
Patients with early-stage ovarian cancer who have not yet undergone chemotherapy may not benefit from this research.
What this research studies
This research focuses on high-grade serous ovarian cancer, which is known for its high mortality rate and resistance to chemotherapy. The study investigates the role of a cytokine called leukemia inhibitory factor (LIF) and its receptor in promoting chemotherapy resistance in ovarian cancer cells. By using advanced techniques like CRISPR and genomic approaches, the research aims to disrupt LIF signaling to make resistant cancer cells more responsive to chemotherapy. The ultimate goal is to develop new therapeutic strategies that could improve treatment outcomes for patients with this challenging condition.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with chemotherapy-resistant ovarian cancer.
How similar studies have gone: Previous research has shown promise in targeting similar pathways in other cancers, suggesting potential for success in this novel approach.
Where this research is happening
-
University of Texas Hlth Science Center
San Antonio, United States Active
Researchers
- Principal investigator: Ebrahimi, Behnam — University of Texas Hlth Science Center
- Study coordinator: Ebrahimi, Behnam
Related research
Other NIH-funded projects on the same topics.
-
Photodynamic lipids to boost chemotherapy for metastatic ovarian cancer
A patient-friendly approach tests a light-activated method to make ovarian cancer metastases more sensitive to chemotherapy.
-
Alternative NF-kB activation after chemotherapy in ovarian cancer
This grant studies how ovarian cancer might come back after chemotherapy by looking at specific signaling pathways in cancer cells and the tumor environment.
-
Understanding how chemotherapy-related changes fuel ovarian cancer relapse
Aims to uncover how changes after chemotherapy help ovarian cancer come back and how to block those signals to help patients stay cancer-free.
-
Protecting hair from ovarian cancer chemotherapy
Trying low-intensity ultrasound to protect the hair of people getting paclitaxel chemotherapy for ovarian cancer.
-
How chemotherapy can activate MASP and help ovarian cancer spread
This project looks at whether common chemotherapy drugs trigger a protein called MASP that helps high-grade serous ovarian cancer cells spread, with the aim of protecting patients from metastatic relapse.
-
Why ovarian cancer can come back after chemotherapy — the role of NF-kB signaling
Researchers are looking at whether signals called alternative NF-kB, triggered after chemotherapy, help drug-resistant tumor-initiating cells survive and cause ovarian cancer to return in women treated for ovarian cancer.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.